Loading
CND Life Sciences
CND Life Sciences is a medical technology and biotechnology company based in Scottsdale, Arizona. Founded in 2017, the company specializes in cutaneous neurodiagnostics to assist in diagnosing neurodegenerative diseases, particularly synucleinopathies like Parkinson’s disease. CND operates a CLIA-certified and CAP-accredited laboratory, providing objective diagnostic testing through minimally invasive skin biopsies. The flagship product, the Syn-One Test®, is the first commercially available test designed to detect and quantify misfolded phosphorylated alpha-synuclein in skin nerve fibers. This test serves as a diagnostic tool for confirming synucleinopathies in patients with conditions such as Parkinson’s disease and dementia with Lewy bodies. CND Life Sciences also offers biomarker services for the biopharmaceutical industry, utilizing its AI-based NerValence system to support clinical trial optimization. The company primarily serves healthcare providers and biopharmaceutical companies, aiming to enhance care for patients with neurodegenerative diseases.
Funding
Every round, secondary, debt facility or acquisition involving CND Life Sciences that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$20M